Nektar Therapeutics buy BiotechBee
Start price
05.01.25
/
60%
€1.09
Target price
31.01.27
€2.50
Performance (%)
-36.08%
End price
30.03.25
€0.69
Summary
This prediction ended on 30.03.25 with a price of €0.69. Massive losses of -36.08% were the result for the BUY prediction by BiotechBee. BiotechBee has 60% into this predictionNektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Nektar Therapeutics | - | - |
| iShares Core DAX® | -1.212% | 1.925% |
| iShares Nasdaq 100 | -4.714% | -1.810% |
| iShares Nikkei 225® | -2.976% | -2.660% |
| iShares S&P 500 | -2.744% | -0.448% |
According to BiotechBee what are the pros and cons of Nektar Therapeutics for the foreseeable future?
Pros
Could be very worthwhile Investment >20% year
Cons
Comments by BiotechBee for this prediction
In the thread Nektar Therapeutics diskutieren
In the thread Trading Nektar Therapeutics
Stopped prediction by BiotechBee for Nektar Therapeutics
Nektar Therapeutics
Start price
Target price
Perf. (%)
€0.72
27.04.25
27.04.25
€1.50
30.04.27
30.04.27
-23.76%
11.05.25
11.05.25
Could be very worthwhile Investment >20% year
Nektar Therapeutics
Start price
Target price
Perf. (%)
€1.59
15.04.24
15.04.24
€2.40
28.02.26
28.02.26
-38.44%
14.12.24
14.12.24
Could be very worthwhile Investment >20% year